TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34152206

Group type: EXPERIMENTAL
Intervention: Conidial suspension (106 conidia mL‐1) of Fusarium oxysporum isolates, applied by pouring 50 ml per pot.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sterile distilled water (control) applied by pouring 50 ml per pot.
Number of subjects: 6
Study: 32939893

Group type: EXPERIMENTAL
Intervention: 3 month lifestyle intervention
Number of subjects: 90
Study: 33993273

Group type: EXPERIMENTAL
Intervention: Combination therapy (β‐lactam plus aminoglycoside or quinolone)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Monotherapy (β‐lactam)
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1119
Study: 32667636

Group type: EXPERIMENTAL
Intervention: Long-acting aripiprazole monohydrate (AOM)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Usual care (clinician's choice, CC)
Number of subjects: 489
Study: 34126275

Group type: EXPERIMENTAL
Intervention: StreetBit app (active alerts for 3 weeks)
Number of subjects: 385

Group type: COMPARATOR
Intervention: StreetBit app (inactive for 3 weeks)
Number of subjects: 385

Group type: COMPARATOR
Intervention: StreetBit app (inactive for 4 weeks post-intervention)
Number of subjects: 385
Study: 32923335

Group type: EXPERIMENTAL
Intervention: Expository classes (G1)
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Tablet-based worked examples (G2)
Number of subjects: 1301
Study: 35765103

Group type: EXPERIMENTAL
Intervention: UC-MSCs (1 × [Formula: see text] cells/kg BW per injection) every other day for three injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study: 33237361

Group type: EXPERIMENTAL
Intervention: tACS (transcranial alternating current stimulation)
Number of subjects: 15

Group type: COMPARATOR
Intervention: RNS (random noise stimulation)
Number of subjects: 15
Study: 36455606

Group type: EXPERIMENTAL
Intervention: 25 mm Hg elastic compression stockings (ECS)
Number of subjects: 341

Group type: COMPARATOR
Intervention: 35 mm Hg elastic compression stockings (ECS)
Number of subjects: 341
Study: 33176886

Group type: EXPERIMENTAL
Intervention: Sodium citrate at 4 mmol/L associated with unfractionated heparin at 10 U/Kg/h (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium citrate at 4 mmol/L (Group A - control)
Number of subjects: 90
Study: 35485381

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously plus standard of care (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care alone (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Secukinumab (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care (group B)
Number of subjects: 50
Study: 33538248

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day
Number of subjects: 27395
Study: 35678785

Group type: EXPERIMENTAL
Intervention: Hypericum and neem oil dressing (1PWD)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Silver-based dressings
Number of subjects: 99
Study: 34849423

Group type: EXPERIMENTAL
Intervention: Telephone navigation to reduce financial strain and address social needs
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Specialized tobacco quitline designed for low-income smokers
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1944
Study: 32219884

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled oral food challenges (DBPCFC)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Parental report of adverse reactions after food consumption
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Overall prevalence estimates for food allergy (FA)
Number of subjects: 6105
Study: 35029306

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32498755

Group type: EXPERIMENTAL
Intervention: F‐PROT + MPT (n 21)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S‐PROT + MPT (n 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo + MPT (PLA; n 19)
Number of subjects: 60
Study: 33424840

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti‐CD24 antibody treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low induced CD24+CD38hi B cells
Number of subjects: 0
Study: 34392115

Group type: EXPERIMENTAL
Intervention: EASE intervention delivered by adult refugees without prior training in mental health
Number of subjects: 146

Group type: COMPARATOR
Intervention: Enhanced control condition
Number of subjects: 146
Study: 32073648

Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg twice daily) plus Cetuximab (500 mg/m2 every 2 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cetuximab (500 mg/m2 every 2 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tivantinib monotherapy
Number of subjects: 78
Study: 35017288

Group type: EXPERIMENTAL
Intervention: Cervical Mobilization (CM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional Treatment (TM)
Number of subjects: 12
Study: 32366314

Group type: EXPERIMENTAL
Intervention: Supported self-management intervention package
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard of care plus asthma education (Control)
Number of subjects: 110
Study: 35556023

Group type: EXPERIMENTAL
Intervention: Enriched Housing (EH) conditions, implemented for 2 hrs/day, 5 days/week for 4 weeks starting 1 week after surgery.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enriched Housing (EH) conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Housing (SH) conditions
Number of subjects: 0
Study: 32762995

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Best-fitting models for EQ-5D and EQ-5D V
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Best-fitting model for VFQ-UI
Number of subjects: 463
Study: 35006497

Group type: EXPERIMENTAL
Intervention: Mother's Own Milk (OMOM)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 133
Study: 36122589

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IHMs) in fifty‐millesimal (LM) potencies
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 34334431

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 3 U/kg/OT
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 6 U/kg/OT
Number of subjects: 235

Group type: COMPARATOR
Intervention: placebo/OT
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (3 and 6 U/kg)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 235
Study: 32132105

Group type: EXPERIMENTAL
Intervention: Higher abundance of CD8+CD45RO‐CCR7‐CD57+ cells
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lower abundance of CD14+CD33+CD85j+ cells
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lower abundance of CD8+CD45RO‐CCR7‐CD57+ cells
Number of subjects: 38

Group type: COMPARATOR
Intervention: Higher abundance of CD14+CD33+CD85j+ cells
Number of subjects: 38
Study: 34316017

Group type: EXPERIMENTAL
Intervention: Midostaurin in addition to intensive chemotherapy
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: JMDsole
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: JMD/TKD1
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: TKD1sole
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 452
Study: 34521933

Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 0
Study: 35697428

Group type: EXPERIMENTAL
Intervention: Anxiety Coach application (AC-app)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 32
Study: 32826637

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) therapy for 3 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Knee extension exercise (KEX) at 25% of one-repetition maximum for 3 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both WBV and KEX
Number of subjects: 11
Study: 35149574

Group type: EXPERIMENTAL
Intervention: Provision of progestogen only pill (POP) with emergency contraception (EC) from pharmacies as routine practice
Number of subjects: 599

Group type: COMPARATOR
Intervention: Rapid-access to sexual and reproductive health (SRH) services
Number of subjects: 599
Study: 32037531

Group type: EXPERIMENTAL
Intervention: Postplacental PPIUD (≤10 minutes)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Immediate PPIUD (>10 minutes)
Number of subjects: 560
Study: 34280069

Group type: EXPERIMENTAL
Intervention: Exergaming using Nintendo Wii Fit™ for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care for 8 weeks
Number of subjects: 0
Study: 34169195

Group type: EXPERIMENTAL
Intervention: Intradialytic cycling (IDC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 109
Study: 36206498

Group type: EXPERIMENTAL
Intervention: Toripalimab 240 mg plus chemotherapy
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Toripalimab 240 mg plus chemotherapy with high tumor mutational burden
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy with high tumor mutational burden
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Toripalimab 240 mg plus chemotherapy with mutations in the focal adhesion-PI3K-Akt signaling pathway
Number of subjects: 465
Study: 33888749

Group type: EXPERIMENTAL
Intervention: Radiomics model based on plain CT images
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 134
Study: 36075242

Group type: EXPERIMENTAL
Intervention: Pirfenidone (2403 mg daily)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 123
Study: 33949727

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T1WI
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T1WI + T2WI-FS
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T2WI-FS
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram based on T1WI
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram based on T2WI-FS
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram based on T1WI + T2WI-FS
Number of subjects: 103
Study: 36296958

Group type: EXPERIMENTAL
Intervention: Exercise + high-protein diet (1.2-1.5 g/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exercise + high-protein and omega-3-enriched diet (2.2 g/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exercise (3x/week)
Number of subjects: 61
Study: 33649056

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (CMFO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo flat cushioning insoles
Number of subjects: 0
Study: 32941530

Group type: EXPERIMENTAL
Intervention: 3PS programme (n = 27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list control group (n = 27)
Number of subjects: 54
Study: 35032704

Group type: EXPERIMENTAL
Intervention: Partially automated driving conditions (L2) with non-driving related tasks (NDRT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Partially automated driving conditions (L2) without NDRT
Number of subjects: 37

Group type: COMPARATOR
Intervention: Manual driving conditions
Number of subjects: 37
Study: 32722819

Group type: EXPERIMENTAL
Intervention: GCK-MODY
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: HNF-MODY
Number of subjects: 162
Study: 34091954

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 35235726

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1490
Study: 33462825

Group type: EXPERIMENTAL
Intervention: Acarbose tablet (50 mg and 100 mg) administered by chewing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Acarbose tablet (50 mg and 100 mg) administered by swallowing
Number of subjects: 24
Study: 36186541

Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching with Four Quadrant Model of Facilitated Learning (OPC+4QM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occupational Performance Coaching alone (OPC)
Number of subjects: 0
Study: 33428347

Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 86
Study: 34648425

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Self-monitoring followed by CBT-I concurrent with PAP
Number of subjects: 118

Group type: COMPARATOR
Intervention: Self-monitoring followed by PAP only
Number of subjects: 118
Study: 33558678

Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 32019736

Group type: EXPERIMENTAL
Intervention: PRBCs with Hb content ≥50 g (Group I, n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Randomly selected PRBCs (Group II, n = 80)
Number of subjects: 160
Study: 35598427

Group type: EXPERIMENTAL
Intervention: Against Stigma Program (60-minute weekly sessions for 6 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual treatment (Control group)
Number of subjects: 70
Study: 34747087

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (Hb transfusion threshold <75 g/L)
Number of subjects: 5092

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (Hb <95 g/L for operating room or ICU; <85 g/L for ward)
Number of subjects: 5092

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 5092
Study: 32828873

Group type: EXPERIMENTAL
Intervention: Over-the-Scope Clip (OTSC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard endoscopic hemostasis (with hemoclips or multipolar electrocoagulation - MPEC)
Number of subjects: 53
Study: 32379240

Group type: EXPERIMENTAL
Intervention: Panax ginseng
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 33237938

Group type: EXPERIMENTAL
Intervention: Middle tertile of AHEI-P score (39.59-56.58)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Lowest tertile of AHEI-P score (<39.59)
Number of subjects: 174
Study: 35697429

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 48

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 48
Study: 33148667

Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin at 45 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin at 90 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin at 120 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin (all doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin (two procedures)
Number of subjects: 16
Study: 32526688

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention (3 sessions, 60-90 minutes each)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 34605077

Group type: EXPERIMENTAL
Intervention: FREMS + usual care
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study: 34331985

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 36 °C
Number of subjects: 57

Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33 °C
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Low rSO2 levels at 24 hours of TTM
Number of subjects: 57
Study: 36252936

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile health application (mHealth) behavioral management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity and mHealth app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study: 34972100

Group type: EXPERIMENTAL
Intervention: Integrated microfinance/livelihood and community‐based rehabilitation (IMCBR) program
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Community‐based rehabilitation (CBR) alone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Care-as-usual (no intervention)
Number of subjects: 210
Study: 33165566

Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV3)
Number of subjects: 24396

Group type: COMPARATOR
Intervention: Inactivated Poliovirus Vaccine (IPV)
Number of subjects: 24396
Study: 33138797

Group type: EXPERIMENTAL
Intervention: mRNA expression quantified using the NanoString nCounter Immunology Panel
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Prediction models based on random Forest using DEGs
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Additive models in edgeR for pre- and post-treatment groups
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards regression model-based survival analysis
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Randomization test for prediction models
Number of subjects: 55
Study: 34281788

Group type: EXPERIMENTAL
Intervention: Two-time micro-osteoperforation (MOP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: One-time micro-osteoperforation (MOP)
Number of subjects: 16
Study: 32035552

Group type: EXPERIMENTAL
Intervention: 16 mg bimekizumab
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 160 mg bimekizumab
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 160 mg bimekizumab with a one-off 320 mg loading dose
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Bimekizumab (all doses combined)
Number of subjects: 206
Study: 35770546

Group type: EXPERIMENTAL
Intervention: Fateh massage
Number of subjects: 84

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 84

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 84
Study: 33558346

Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Christian prayer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific strategy)
Number of subjects: 0
Study: 36099136

Group type: EXPERIMENTAL
Intervention: Synchronous and metachronous other primary cancer
Number of subjects: 244

Group type: COMPARATOR
Intervention: No synchronous and metachronous other primary cancer
Number of subjects: 244
Study: 33284116

Group type: EXPERIMENTAL
Intervention: App-based diet tracking plus feedback on DASH adherence via text message
Number of subjects: 59

Group type: COMPARATOR
Intervention: App-based diet tracking (active comparator)
Number of subjects: 59
Study: 35607975

Group type: EXPERIMENTAL
Intervention: Daily written updates on the satisfaction and psychologic symptoms of families of ICU patients
Number of subjects: 252
Study: 33821928

Group type: EXPERIMENTAL
Intervention: Minimal Contact Cognitive Behavioral Therapy (MC-CBT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard Cognitive Behavioral Therapy (S-CBT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Education/Support (EDU)
Number of subjects: 145
Study: 33357641

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg twice-daily
Number of subjects: 637

Group type: COMPARATOR
Intervention: enalapril 10 mg twice-daily
Number of subjects: 637
Study: 34473295

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily for 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34264296

Group type: EXPERIMENTAL
Intervention: Combined Atropine and Patching Therapy (CAPT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Patching alone
Number of subjects: 108
Study: 32433510

Group type: EXPERIMENTAL
Intervention: Seattle‐PAP
Number of subjects: 232

Group type: COMPARATOR
Intervention: FP‐CPAP
Number of subjects: 232
Study: 34775781

Group type: EXPERIMENTAL
Intervention: Efpeglenatide
Number of subjects: 618
Study: 34286560

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg plus nutritional supplement (Panax ginseng, Moringa Oleifera, Rutin) once daily for 3 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Tadalafil 5 mg plus placebo once daily for 3 months
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 86
Study: 32668113

Group type: EXPERIMENTAL
Intervention: Roflumilast 0.3% cream
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Roflumilast 0.15% cream
Number of subjects: 331

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Roflumilast 0.3% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Roflumilast 0.15% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Vehicle cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Number of subjects: 331
Study: 34420102

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 81
Study: 33786980

Group type: EXPERIMENTAL
Intervention: Vacuum Sealing Drainage (VSD)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine Dressing Change (RDC)
Number of subjects: 130
Study: 32745165

Group type: EXPERIMENTAL
Intervention: Radial Access
Number of subjects: 2119

Group type: EXPERIMENTAL
Intervention: Femoral Access
Number of subjects: 2119
Study: 35093794

Group type: EXPERIMENTAL
Intervention: Communicating three benefits of a policy
Number of subjects: 4616

Group type: EXPERIMENTAL
Intervention: Communicating one benefit of a policy
Number of subjects: 4616
Study: 32885526

Group type: EXPERIMENTAL
Intervention: Partial meal-replacement (pMR) hypocaloric diet for 12 weeks
Number of subjects: 122